https://doi.org/10.4081/acbr.2023.322
A rare case of Hyperphosphatemic Tumoral Calcinosis in a 13 year old Nigerian boy
Submitted: 20 March 2023
Accepted: 15 May 2023
Published: 15 June 2023
Accepted: 15 May 2023
Abstract Views: 219
PDF: 61
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Tumoral calcinosis is a rare disorder that presents with ectopic calcifications deposited at different periarticular soft tissue regions of the body- mostly hips, elbows and shoulders. It results from a relative deficiency of, or resistance to, the phosphate-regulating hormone - Fibroblast Growth Factor 23 (FGF23), due to gene mutations, causing hyperphosphatemia. We describe this condition in a 13 year old, Nigerian boy who presented with a 7 year history of multiple body swellings of firm to hard consistency. Laboratory investigations showed hyperphosphatemia with normal serum calcium, vitamin D and parathyroid hormone levels. Radiological and histological findings were consistent with tumoral calcinosis. Having had two previous surgeries to remove the lesions, he was now commenced on low phosphate diet and phosphate binders. It is important to differentiate tumoral calcinosis from other causes of pathological calcification using clinical and laboratory findings especially in environments where molecular genetic testing is not readily available.
Boskey AL, Vigorita VJ, Sencer O, et al. Chemical, microscopic, and ultrastructural characterization of the mineral deposits in tumoral calcinosis. Clin Orthop Relat Res 1983;178:258–69.
DOI: https://doi.org/10.1097/00003086-198309000-00036
Slavin RE, Wen J, Kumar D, Evans EB. Familial tumoral calcinosis. A clinical, histopathologic, and ultrastructural study with an analysis of its calcifying process and pathogenesis. Am J Surg Pathol 1993;17:788–802.
DOI: https://doi.org/10.1097/00000478-199308000-00004
Annamunthodo H. Calcinosis. Am J Surg 1960;99:951–5.
DOI: https://doi.org/10.1016/0002-9610(60)90496-7
Ramnitz MS, Gourh P, Goldbach-Mansky R, et al. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome. J Bone Miner Res 2016;31:1845–54.
DOI: https://doi.org/10.1002/jbmr.2870
Ichikawa S, Baujat G, Seyahi A, et al. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A 2010;152a:896– 903.
DOI: https://doi.org/10.1002/ajmg.a.33337
Olauson H, Krajisnik T, Larsson C, et al. A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome. Eur J Endocrinol 2008;158:929–34.
DOI: https://doi.org/10.1530/EJE-08-0011
Hershkovitz D, Gross Y, Nahum S, et al. Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis. J Invest Dermatol 2011;131:662–9.
DOI: https://doi.org/10.1038/jid.2010.387
Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genetics 2004;36:579– 81.
DOI: https://doi.org/10.1038/ng1358
Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005;14:385–90.
DOI: https://doi.org/10.1093/hmg/ddi034
Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007;117:2684–91.
DOI: https://doi.org/10.1172/JCI31330
Polykandriotis EP, Beutel FK, Horch RE, Grünert J. A case of tumoral calcinosis in a neonate and review of the literature. Arch Orthop Trauma 2004;124:563-73.
DOI: https://doi.org/10.1007/s00402-004-0715-0
Onuigbo WI. Patterns of tumoral calcinosis in Nigeria and Papua New Guinea. P N G Med J 1977;20:78-9.
Kolawole TM, Bohrer SP. Tumoral calcinosis with "fluid levels" in the tumoral masses. American Journal of Roentgenology 1974;120:461-5.
DOI: https://doi.org/10.2214/ajr.120.2.461
Mallick S, Ahmad Z, Gupta AK, Mathur SR. Hyperphosphatemic tumoral calcinosis. BMJ Case Rep 2013;2013:bcr2013008728.
DOI: https://doi.org/10.1136/bcr-2013-008728
Narchi H. Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis. Pediatrics 1997;99:745–8.
DOI: https://doi.org/10.1542/peds.99.5.745
Ogunlade SO, Salawu SA, Eyelade RA. Tumoral calcinosis: a report of a case. African Journal of Biomedical Research 2002;5:91-2.
Ebong WW, Kolawole TM. Tumoral calcinosis associated with Rheumatoid arthritis and Sickle cell anaemia. The Central African Journal of Medicine.1984;30:107-110.
Slavin RE, Wen J, Barmada A. Tumoral calcinosis—a pathogenetic overview: a histological and ultrastructural study with a report of two new cases, one in infancy. Int J Surg Pathol 2012;20:462–73.
DOI: https://doi.org/10.1177/1066896912444925
Enzinger & Weiss's Soft Tissue Tumors, Sixth Edition. 2014. Elsevier, Amsterdam, The Netherlands. 1268 pp.
Carmichael KD, Bynum JA, Evans EB. Familial tumoral calcinosis: a forty-year follow-up on one family. J Bone Joint Surg Am 2009;91:664–71.
DOI: https://doi.org/10.2106/JBJS.G.01512
Lammoglia JJ, Mericq V. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. Horm Res 2009;71:178–84.
DOI: https://doi.org/10.1159/000197876
Alkhooly AZ. Medical treatment for tumoral calcinosis with eight years of follow-up: a report of four cases. J Orthop Surg 2009;17:379–82.
DOI: https://doi.org/10.1177/230949900901700328
Yancovitch A, Hershkovitz D, Indelman M, et al. Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis. J Bone Miner Metab 2011;29:621–5.
DOI: https://doi.org/10.1007/s00774-011-0260-1
Nggada HA, Eni UE, Lawan MA, et al. Recurrent tumoral calcinosis. Tropical Doctor 2006;36:240-1.
DOI: https://doi.org/10.1258/004947506778604913
Olsen KM, Chew FS. Tumoral calcinosis: pearls, polemics, and alternative possibilities. Radiographics 2006;26:871–85.
DOI: https://doi.org/10.1148/rg.263055099
How to Cite
Nnakenyi, I., Edoga, C., Nnakenyi, E., Iloanusi, N., & Okwor, C. (2023). A rare case of Hyperphosphatemic Tumoral Calcinosis in a 13 year old Nigerian boy. Annals of Clinical and Biomedical Research, 4(1). https://doi.org/10.4081/acbr.2023.322
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.